66
Participants
Start Date
April 30, 2004
Primary Completion Date
December 31, 2005
Study Completion Date
March 31, 2008
bendamustine and rituximab
Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
Royal Melbourne Hospital, Parkville
Peter MacCallum Cancer Institute, East Melbourne
Arena Oncology Associates, Great Neck
Long Island Jewish Medical Center, New Hyde Park
Upstate NY Cancer Research & Education Foundation, Inc. - Interlakes Oncology/Hematology, Rochester
Georgetown University Medical Center - Lombardi Cancer Center, Washington D.C.
Univ. of Virginia Health System-Cancer Center Clinical Trials Office, Charlottesville
Suburban Hematology & Oncology Associates, Lawrenceville
Georgia Oncology Partners Research and Education Foundation, Macon
John B. Amos Cancer Center, Columbus
Pasco Hernando Oncology, New Port Richey
ACORN - West Cancer Center, Memphis
Northern Indiana Cancer Research Consortium, South Bend
University of Michigan Comprehensive Cancer Center, Ann Arbor
Hubert H. Humphrey Cancer Center, Robbinsdale
LSU Health Sciences Center, Shreveport
Baylor University Medical Center, Dallas
Southwest Regional Cancer Center, Austin
USC/Kenneth Norris Jr. Cancer Hospital and Research Institute, Los Angeles
Wilshire Oncology Medical Group, La Verne
San Diego Cancer Center, Vista
Bay Area Cancer Research Group, Concord
Alaska Cancer Research and Education Center, Anchorage
Hematology Oncology, P.C. Carl and Dorothy Bennett Cancer Center, Stamford
Oncology and Hematology, Metairie
Beth Israel/Deaconess Medical Center, Boston
The Cancer Institute of New Jersey, New Brunswick
St. Vincent's Hospital, Darlinghurst
Westmead Hospital, Westmead
Queen Elizabeth II Health Sciences Centre-Victoria General Site, Halifax
The Royal Victoria Hospital Cancer Care Program Clinical Trials, Barrie
North Eastern Ontario Regional Cancer Center, Greater Sudbury
Ottawa Hospital Research Institute, Ottawa
Hopital Notre-Dame Du Chum, Montreal
Lead Sponsor
Cephalon
INDUSTRY